Immunosuppressant treatment to help low blood counts in some bone marrow disorders
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a group of immune-suppressing medicines (with steroids and growth-factor injections) for people with aplastic anemia or certain low-risk myelodysplastic syndromes. The goal is to improve bone marrow function and reduce problems caused by low blood counts, such as fatigue, infections, or bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have either aplastic anemia, or a low or intermediate-risk myelodysplastic syndrome (MDS), including “hypocellular” types.
- Your last chemotherapy, targeted therapy, or immune-suppressing medicines (other than steroids) were stopped at least 2 weeks ago, and side effects are back to mild or better.
- Your organs are working well enough (liver and kidney blood tests are within the trial’s limits).
- You’re generally able to do daily activities (performance status score of 2 or less).
- You need treatment because of symptoms or complications from low blood counts (like transfusions, severe fatigue, bleeding, or frequent infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests whether adding dexamethasone, intravenous immunoglobulin, and extra donor cells can lower donor-specific antibodies in people receiving half-matched stem cell transplants. The goal is to help more patients safely get a transplant when fully matched donors aren't available.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.